Key Insights

Highlights

Success Rate

92% trial completion (above average)

Published Results

20 trials with published results (14%)

Research Maturity

71 completed trials (50% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

4.2%

6 terminated out of 142 trials

Success Rate

92.2%

+5.7% vs benchmark

Late-Stage Pipeline

12%

17 trials in Phase 3/4

Results Transparency

28%

20 of 71 completed with results

Key Signals

20 with results92% success

Data Visualizations

Phase Distribution

99Total
Not Applicable (33)
P 1 (17)
P 2 (32)
P 3 (10)
P 4 (7)

Trial Status

Completed71
Unknown30
Recruiting16
Not Yet Recruiting9
Terminated6
Withdrawn4

Trial Success Rate

92.2%

Benchmark: 86.5%

Based on 71 completed trials

Clinical Trials (142)

Showing 20 of 20 trials
NCT07631377Phase 4Not Yet Recruiting

The LalelaLung Study: Digital Stethoscope Clinical Evaluation

NCT06526221Not ApplicableEnrolling By InvitationPrimary

Evaluating Urine Isoniazid Testing to Detect Nonadherence to Tuberculosis Medications in India

NCT04575519Phase 2TerminatedPrimary

Adjunctive Acetylsalicylic Acid and Ibuprofen for Tuberculosis

NCT06253715Phase 3Recruiting

Shortened Regimen for Drug-susceptible TB in Children

NCT05285202Not ApplicableRecruitingPrimary

Clinic-based Versus Hotspot-focused Active TB Case Finding

NCT04844502Not ApplicableCompletedPrimary

Cardiopulmonary Function and Quality of Life in Pulmonary Tuberculosis

NCT05007821Phase 2Completed

Linezolid Dosing Strategies in Drug-Resistant TB

NCT06845618Recruiting

Blood Tuberculosis DNA Levels to Monitor Tuberculosis Treatment

NCT06205589Phase 2Not Yet RecruitingPrimary

Therapeutic ID93 + GLA-SE Vaccination in Participants With Rifampicin-Susceptible Pulmonary TB

NCT07077213RecruitingPrimary

18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients

NCT04752592Not ApplicableCompletedPrimary

Evaluation of a Rapid Point-of-Care Serological Triage Test for Active TB

NCT03512249Phase 2CompletedPrimary

Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence

NCT05556746Phase 2Active Not RecruitingPrimary

Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB

NCT06057519Phase 3RecruitingPrimary

Pragmatic Optimized Rifampicin Trial

NCT07350356Completed

Bronchoscopic Role in Early Detection of Endobronchial Tuberculosis in Suspected Pulmonary Tuberculosis Patients.

NCT06441006Phase 2RecruitingPrimary

Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis

NCT07313995Not ApplicableNot Yet RecruitingPrimary

Digital Health Intervention to Improve TPT Uptake

NCT05455112Phase 2CompletedPrimary

Safety and Efficacy of RUTI® With the Standard of Treatment for Tuberculosis

NCT04919239Phase 2CompletedPrimary

Clinical Trial to Investigate Therapeutic Vaccine (RUTI) Against Tuberculosis (TB)

NCT07271225Not ApplicableRecruitingPrimary

Safety and Efficacy of Ear Acupuncture for Antituberculosis Drug-Related Nausea and Vomiting

Scroll to load more

Research Network

Activity Timeline